Laura Kleiman Ph.D.

Year of Graduation: 

2010

Advisors/Lab: 

Prof. Peter K. Sorger and Prof. Douglas Lauffenburger

Current Position: 

Founder and CEO of Reboot Rx

Reboot Rx

Thesis Title: Experimental and computational analysis of epidermal growth factor receptor pathway phosphorylation dynamics

 

Publications while at MIT: 

1. Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers.

Kleiman LB, Krebs AM, Kim SY, Hong TS, Haigis KM.

PLoS One. 2013 Dec 12;8(12):e82982. doi: 10.1371/journal.pone.0082982. eCollection 2013.

PMID:24349411  Free PMC Article

 

2. Future prospects for leveraging molecular information in the fight against colorectal cancer.

Kleiman LB, Haigis KM.In: Haigis KM (ed) Molecular pathogenesis of colorectal cancer. Springer, New York (2013) pp. 303-308.

 

3. Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding.

Kleiman LB, Maiwald T, Conzelmann H, Lauffenburger DA, Sorger PK.

Mol Cell. 2011 Sep 2;43(5):723-37. doi: 10.1016/j.molcel.2011.07.014.

PMID:21884975 Free PMC Article

 

4. Dynamics, stability and inheritance of somatic DNA methylation imprints.

Sontag LB, Lorincz MC, Georg Luebeck E.

J Theor Biol. 2006 Oct 21;242(4):890-9. Epub 2006 May 20.

PMID:16806276

 

5. Evaluation of pathways for progression of heterogeneous breast tumors.

Sontag L, Axelrod DE.

J Theor Biol. 2005 Jan 21;232(2):179-89.

PMID:15530488

 

Linkedin Profile